Chatterton & Associates
VRTX icon

Chatterton & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Chatterton & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$331K Sell
634
-1
-0.2% -$512 0.15% 78
2026
Q2 		$315K Buy
635
+66
+12% +$29.2K 0.19% 74
2026
Q1 		$254K Buy
569
+74
+15% +$34.5K 0.18% 83
2025
Q4 		$224K Buy
+495
New +$213K 0.19% 75

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Chatterton & Associates's VRTX Position: Q3 2026 in Review

Chatterton & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 0.16% in Q3 2026, selling an estimated $512 and leaving 634 shares worth $331K. The position accounts for 0.15% of the portfolio, ranked #78.

Chatterton & Associates first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Chatterton & Associates held 634 shares of Vertex Pharmaceuticals worth $331K as of Q3 2026.
  • Chatterton & Associates sold 1 Vertex Pharmaceuticals share in Q3 2026, an estimated $512.
  • Vertex Pharmaceuticals made up 0.15% of Chatterton & Associates's portfolio in Q3 2026, its #78 holding.
  • Chatterton & Associates first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Chatterton & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.